HuGE Literature Finder
Records 1-28
|
The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
International journal of cancer 2021 Apr . Cai Lei, Chen Yong, Tong Xiaoling, Wu Xue, Bao Hua, Shao Yang, Luo Zhuang, Wang Xuming, Cao Ya |
|
GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Journal of cancer research and clinical oncology 2020 Dec . Plum Patrick Sven, Löser Heike, Zander Thomas, Essakly Ahlem, Bruns Christiane J, Hillmer Axel M, Alakus Hakan, Schröder Wolfgang, Büttner Reinhard, Gebauer Florian, Quaas Alexand |
|
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology 2020 Jan . Lin G, Li C, Li P S, Fang W Z, Xu H P, Gong Y H, Zhu Z F, Hu Y, Liang W H, Chu Q, Zhong W Z, Wu L, Wang H J, Wang Z J, Li Z M, Lin J, Guan Y F, Xia X F, Yi X, Miao Q, Wu B, Jiang K, Zheng X B, Zhu W F, Zheng X L, Huang P S, Xiao W J, Hu D, Zhang L F, Fan X R, Mok T S K, Huang |
|
Role of screening colonoscopy for colorectal tumors in Helicobacter pylori-related chronic gastritis with MDM2 SNP309 G/G homozygous: A prospective cross-sectional study in Thailand.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2018 Sep 29 (5): 555-560. Tongtawee Taweesak, Simawaranon Theeraya, Wattanawongdon Warepo |
|
Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.
Oncotarget 2017 Nov 8 (61): 104123-104135. Ten Kate Fiebo J C, Suzuki Lucia, Dorssers Lambert C J, Dinjens Winand N M, Jones David T W, Nieboer Daan, Doukas Michael, Van Lanschot J Jan B, Wijnhoven Bas P L, Looijenga Leendert H J, Biermann Kathari |
|
Colorectal carcinoma with osseous metaplasia.
Oncotarget 2017 Sep 8 (39): 65407-65413. Liu Xibo, Xu Jinghong, Chen Liro |
|
MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients.
Journal of Cancer 2017 8 (12): 2154-2162. Deben Christophe, Op de Beeck Ken, Van den Bossche Jolien, Jacobs Julie, Lardon Filip, Wouters An, Peeters Marc, Van Camp Guy, Rolfo Christian, Deschoolmeester Vanessa, Pauwels Patri |
|
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Sep 11 (9): 1493-502. Schrock Alexa B, Frampton Garrett M, Suh James, Chalmers Zachary R, Rosenzweig Mark, Erlich Rachel L, Halmos Balazs, Goldman Jonathan, Forde Patrick, Leuenberger Kurt, Peled Nir, Kalemkerian Gregory P, Ross Jeffrey S, Stephens Philip J, Miller Vincent A, Ali Siraj M, Ou Sai-Hong Ignati |
|
Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Cancer medicine 2016 May . Enokida Yasuaki, Shimizu Kimihiro, Atsumi Jun, Kakegawa Seiichi, Takase Yoshiaki, Kaira Kyoichi, Yashima Hideaki, Araki Takuya, Nakazawa Seshiru, Ohtaki Yoichi, Nagashima Toshiteru, Alexander Lezhava, Usui Kengo, Ishikawa Toshihisa, Hayashizaki Yoshihide, Takeyoshi Izu |
|
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Oncotarget 2016 Mar . Lim Sun Min, Kim Eun Young, Kim Hye Ryun, Ali Siraj M, Greenbowe Joel R, Shim Hyo Sup, Chang Hyun, Lim Seungtaek, Paik Soonmyung, Cho Byoung Ch |
|
Murine Double-Minute 2 Homolog Single Nucleotide Polymorphisms 285 and 309 in Cervical Carcinogenesis.
Molecular diagnosis & therapy 2015 Aug 19 (4): 235-44. Roszak Andrzej, Misztal Matthew, Sowi?ska Anna, Jagodzi?ski Pawel |
|
Correction: impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
PloS one 2015 10 (4): e0126295. Authors are not available |
|
Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
PloS one 2015 10 (3): e0118829. Hori Yasuki, Miyabe Katsuyuki, Yoshida Michihiro, Nakazawa Takahiro, Hayashi Kazuki, Naitoh Itaru, Shimizu Shuya, Kondo Hiromu, Nishi Yuji, Umemura Shuichiro, Kato Akihisa, Ohara Hirotaka, Inagaki Hiroshi, Joh Takas |
|
Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Cancer biology & therapy 2014 15 (11): 1542-51. Zheng Datong, Chen Yanping, Gao Caijie, Wei Yongyue, Cao Guochun, Lu Nan, Hou Yayi, Jiang Xiuqin, Wang Jianj |
|
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Journal of gastroenterology and hepatology 2013 Sep 28 (9): 1482-8. Renouf Daniel J, Zhai Rihong, Sun Bin, Xu Wei, Cheung Winson Y, Heist Rebecca S, Kulke Matthew H, Cescon David, Asomaning Kofi, Marshall Ariella L, Li Su, Christiani David C, Liu Geoffr |
|
Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients.
Disease markers 2013 35 (6): 701-10. Cintra Hellen Silva, Pinezi Juliana Castro Dourado, Machado Graziella Dias Pinheiro, de Carvalho Gustavo Moura, Carvalho Ana Terra Silva, dos Santos Thalles Eduardo Dias, Marciano Ricardo Duarte, Soares Renata de Bastos Ascen |
|
P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
Asian Pacific journal of cancer prevention : APJCP 2013 14 (9): 5415-20. Ren Yang-Wu, Yin Zhi-Hua, Wan Yan, Guan Peng, Wu Wei, Li Xue-Lian, Zhou Bao-S |
|
SNP (-617C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women.
PloS one 2013 8 (9): e73794. Okano Yasuko, Nezu Uru, Enokida Yasuaki, Lee Ming Ta Michael, Kinoshita Hiroko, Lezhava Alexander, Hayashizaki Yoshihide, Morita Satoshi, Taguri Masataka, Ichikawa Yasushi, Kaneko Takeshi, Natsumeda Yutaka, Yokose Tomoyuki, Nakayama Haruhiko, Miyagi Yohei, Ishikawa Toshihi |
|
Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2011 Jan 15 (1): 48-56. Boonstra Jurjen J, van Marion Ronald, Tilanus Hugo W, Dinjens Winand N |
|
MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Pancreas 2010 Jan 39 (1): 76-80. Grochola Lukasz F, Müller Thomas H, Bond Gareth L, Taubert Helge, Udelnow Andrej, Würl Pet |
|
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 15 (9): 3103-9. Cescon David W, Bradbury Penelope A, Asomaning Kofi, Hopkins Jessica, Zhai Rihong, Zhou Wei, Wang Zhaoxi, Kulke Matthew, Su Li, Ma Clement, Xu Wei, Marshall Ariela L, Heist Rebecca Suk, Wain John C, Lynch Thomas J, Christiani David C, Liu Geoffr |
|
p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E 2009 Mar . Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC |
|
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Annals of surgical oncology 2009 Feb 16 (2): 431-9. Chen Jinyun, Li Donghui, Killary Ann M, Sen Subrata, Amos Christopher I, Evans Douglas B, Abbruzzese James L, Frazier Marsha |
|
Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2008 Oct 12 (10): 1664-72; discussion 1672-3. Franko Jan, Krasinskas Alyssa M, Nikiforova Marina N, Zarnescu Narcis O, Lee Kenneth K W, Hughes Steven J, Bartlett David L, Zeh Herbert J, Moser A Jam |
|
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 14 (12): 4010-5. Asomaning Kofi, Reid Amy E, Zhou Wei, Heist Rebecca S, Zhai Rihong, Su Li, Kwak Eunice L, Blaszkowsky Lawrence, Zhu Andrew X, Ryan David P, Christiani David C, Liu Geoffr |
|
Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Carcinogenesis 2007 Sep 28 (9): 1996-2001. Yang Ming, Guo Yongli, Zhang Xuemei, Miao Xiaoping, Tan Wen, Sun Tong, Zhao Dan, Yu Dianke, Liu Junniao, Lin Dongx |
|
MDM2 309T>G polymorphism and risk of lung cancer in a Korean population.
Lung cancer (Amsterdam, Netherlands) 2006 Oct 54 (1): 19-24. Park Sun Ha, Choi Jin Eun, Kim Eun Jin, Jang Jin Sung, Han Hyung Soo, Lee Won Kee, Kang Young Mo, Park Jae Yo |
|
Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix.
Cancer genomics & proteomics 0 17 (5): 627-641. Jung Hera, Bae Go Eun, Kim Hye Min, Kim Hyun-S |
- Page last reviewed:Oct 1, 2020
- Page last updated:Sep 22, 2021
- Content source: